Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Prospective Intestinal Ultrasound Study for Artificial Intelligence Algorithm Development (PSIUSAD)

9 września 2026 zaktualizowane przez: Matthew Smyth, University of British Columbia

Prospective Study for Intestinal Ultrasound Algorithm Development

This observational study will use intestinal ultrasound images to help develop computer programs that may make it easier to assess bowel inflammation.

The study will include adults who are healthy or who are having an intestinal ultrasound as part of care for inflammatory bowel disease, such as Crohn disease or ulcerative colitis. Researchers want to find out whether a computer program can measure bowel wall thickness from ultrasound images as accurately as experienced ultrasound clinicians. They will also explore whether the program can identify other changes in the bowel.

Participants will have an intestinal ultrasound as part of their usual care. People who agree to take part will allow the research team to use de-identified ultrasound images and a small amount of related health information. No medication, experimental treatment, or additional ultrasound procedure will be given for this study. The computer program will not be used to make decisions about a participant's care, and participants will not receive individual results from the program.

Przegląd badań

Status

Jeszcze nie rekrutacja

Szczegółowy opis

Inflammatory bowel disease, including Crohn disease and ulcerative colitis, requires reliable assessment of intestinal inflammation to support clinical monitoring and treatment decisions. Intestinal ultrasound is a non-invasive, point-of-care imaging method that can assess bowel inflammation without radiation exposure. However, its interpretation may vary by operator experience and local scanning practice.

This prospective, multicentre, observational study will collect de-identified intestinal ultrasound images, cine loops, and limited associated metadata from adults aged 18 years and older. Eligible participants may be healthy individuals with no known inflammatory bowel disease or individuals undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Intestinal ultrasound examinations will be performed as part of routine clinical care. The study does not add a treatment intervention, investigational drug, experimental device, or clinically directed diagnostic procedure.

Following informed consent, ultrasound images and cine loops generated during the routine examination will be exported in de-identified DICOM format. Limited information relevant to artificial intelligence development and validation, such as age, sex, self-reported race, pregnancy status, eligibility confirmation, and relevant scan-related or pre-existing clinical information, may also be recorded. Direct personal identifiers and personal health information will be removed before the data are transferred outside the clinical site.

The de-identified data will be reviewed for appropriate de-identification and formatting before secure transfer to Dova Health Intelligence Inc. The data will be annotated and used to develop, train, tune, and test computer vision algorithms designed to identify bowel structures and measure bowel wall thickness on intestinal ultrasound. The study will also assess the feasibility of developing algorithms to evaluate bowel wall layer stratification, luminal diameter, bowel wall flow, bowel wall scarring, gastrointestinal motility, and mesenteric fat proliferation.

The primary objective is to evaluate whether the computer vision algorithm prototype can measure bowel wall thickness with performance comparable to manual measurements by experienced sonographers. Secondary objectives include evaluating the quality, diversity, and usability of the collected ultrasound data for artificial intelligence development and assessing the feasibility of measuring additional intestinal ultrasound features.

The algorithms developed in this study are investigational and will not be used in routine clinical care during the study. No participant-level algorithm findings will be returned to participants, and participation is not expected to provide a direct clinical benefit. The primary foreseeable risk is a loss of confidentiality; this risk is mitigated through de-identification at the study site, verification of de-identification before transfer, secure file transfer, controlled access, and secure cloud-based storage. The study plans to enroll up to 95 participants internationally, including up to 30 participants at the British Columbia site.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

95

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • British Columbia
      • Vancouver, British Columbia, Kanada, V6Z 2L2
        • IBD Centre of BC
        • Kontakt:
        • Główny śledczy:
          • Matthew J Smyth, MD

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Tak

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

The study population will consist of adults aged 18 years and older who are either healthy or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Participants will be recruited through the IBD Centre of BC and other participating study sites. The study may include individuals with inflammatory bowel disease and healthy volunteers. The study aims to include a diverse participant population to support evaluation of artificial intelligence algorithm performance across different participant characteristics.

Opis

Inclusion Criteria:

  • Adults aged 18 years or older.
  • Individuals who are either healthy with no known finding of inflammatory bowel disease before the ultrasound examination or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason.
  • Individuals who are able and willing to provide informed consent for the collection and use of de-identified study data.

Exclusion Criteria:

  • Individuals who do not meet the study demographic requirements.
  • Individuals unable or unwilling to provide informed consent.
  • Pregnant individuals.
  • Individuals with health conditions managed using drugs or medical-device intervention, or with unmanaged conditions or conditions requiring monitoring, that could affect study eligibility or the ultrasound assessment.
  • Individuals who have recently taken contrast-enhancing compounds.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Intestinal Ultrasound Participants
This cohort includes adults aged 18 years and older who are either healthy or undergoing intestinal ultrasound for inflammatory bowel disease screening, monitoring, or another clinical reason. Participants will undergo intestinal ultrasound as part of routine clinical care. With informed consent, de-identified ultrasound images and cine loops, along with limited associated information such as age, sex, self-reported race, and relevant scan-related details, will be collected for artificial intelligence algorithm development. No study drug, experimental treatment, or experimental device will be administered. The artificial intelligence algorithms will not be used to guide participant care or provide individual diagnostic results during the study.
Intestinal ultrasound images and cine loops will be collected from adults undergoing ultrasound as part of routine clinical care. Following informed consent, the images and cine loops will be de-identified and used for artificial intelligence algorithm development, training, tuning, and testing. The study does not assign participants to receive an intervention, and the ultrasound is not performed solely for research purposes. The artificial intelligence algorithms developed using the data will not be used to guide participant care or provide individual diagnostic results during the study.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Artificial Intelligence-Generated Bowel Wall Thickness Measurement Agreement
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Agreement between bowel wall thickness measurements generated by the artificial intelligence computer-vision algorithm and manual bowel wall thickness measurements performed by experienced sonographers using de-identified intestinal ultrasound images and cine loops. Agreement will be assessed using the pre-specified performance metric in the statistical analysis plan.
Day 1, after completion of the intestinal ultrasound examination

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Bowel Wall Layer Stratification Feasibility
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall layer stratification.
Day 1, after completion of the intestinal ultrasound examination
Luminal Diameter Measurement Feasibility
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable luminal diameter measurement.
Day 1, after completion of the intestinal ultrasound examination
Bowel Wall Flow Assessment Feasibility
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall flow assessment.
Day 1, after completion of the intestinal ultrasound examination
Bowel Wall Scarring Assessment Feasibility
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable bowel wall scarring assessment.
Day 1, after completion of the intestinal ultrasound examination
Gastrointestinal Motility Assessment Feasibility
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable gastrointestinal motility assessment.
Day 1, after completion of the intestinal ultrasound examination
Mesenteric Fat Proliferation Assessment Feasibility
Ramy czasowe: Day 1, after completion of the intestinal ultrasound examination
Proportion of de-identified intestinal ultrasound images and cine loops for which the artificial intelligence algorithm generates an interpretable assessment of mesenteric fat proliferation.
Day 1, after completion of the intestinal ultrasound examination
Proportion of Cine Loops Suitable for AI Development
Ramy czasowe: At completion of dataset preparation
Percentage of collected de-identified cine loops that meet all pre-specified completeness, image-quality, and required-metadata criteria for artificial intelligence algorithm training, tuning, and testing.
At completion of dataset preparation

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Matthew J Smyth, MD, University of British Columbia, IBD Centre of BC

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 września 2026

Zakończenie podstawowe (Szacowany)

1 lutego 2027

Ukończenie studiów (Szacowany)

1 lutego 2027

Daty rejestracji na studia

Pierwszy przesłany

2 września 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 września 2026

Pierwszy wysłany (Rzeczywisty)

10 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

10 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant-level data will not be made available to external researchers. The study will collect de-identified intestinal ultrasound images, cine loops, and limited associated information for use by Dova Health Intelligence Inc. in quality assessment, annotation, artificial intelligence algorithm training, tuning, testing, and related future algorithm-development activities described in the study protocol. Data will not be made publicly available or shared outside the authorized study collaborators.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj